Said Farschtschi

Also affiliated with University Medical Center Hamburg-Eppendorf

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 2 papers. Top paper: “Efficacy and safety of selumetinib in adults with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas (KOMET): a multicentre, international, randomised, placebo-controlled, parallel, double-blind, phase 3 study”.

Efficacy and safety of selumetinib in adults with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas (KOMET): a multicentre, international, randomised, placebo-controlled, parallel, double-blind, phase 3 study

The Lancet(2025)10.1016/s0140-6736(25)00986-9

N/A

0.707DataRank · unranked

39 citations

Geraldine O’Sullivan Coyne, Pamela L. Wolters, Staci Martin, Said Farschtschi, Ignacio Blanco +38 more

Malignant peripheral nerve sheath tumors in neurofibromatosis type 1 arise from distinct nodular lesions: A retrospective imaging analysis

Neuro-Oncology Advances(2025)10.1093/noajnl/vdaf201

N/A

0DataRank · unranked

5 citations

Brigitte C. Widemann, Andrea M. Gross, Andrea Baldwin, Said Farschtschi, Victor‐Felix Mautner +2 more